Osiris Therapeutics (OSIR) Tops Q3 Revs, Loss Views

November 5, 2012 8:08 AM EST Send to a Friend
Osiris Therapeutics (NASDAQ: OSIR) reported Q3 EPS of ($0.09), $0.05 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $2.15 million versus the consensus estimate of $1.89 million.

For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment